title: Tadalafil-associated priapism.
abstract: A healthy 46-year-old man presented to the Emergency Department with a 36-hour history of persistent, painful erection after taking the cyclic guanylyl monophosphate-specific phosphodiesterase 5 inhibitor tadalafil. He had no other identified contributing factors for priapism. After confirmation of ischemic priapism and failure of bedside management in the Emergency Department, the patient underwent operative caverno-spongiosal shunting. Postoperatively, the erection initially rebounded but gradually receded with manual compression over 48 hours. At outpatient follow-up, the patient remained flaccid without erections. To our knowledge, this is the first report of tadalafil-associated priapism.
authors.affiliation: Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA. shking@u.washington.edu
authors.forename: Stephen H
authors.initials: SH
authors.lastname: King
authors.forename: Maralyn
authors.initials: M
authors.lastname: Hallock
authors.forename: Jared
authors.initials: J
authors.lastname: Strote
authors.forename: Hunter
authors.initials: H
authors.lastname: Wessells
mesh_terms: D000328:Adult; D002243:Carbolines / Q000009:adverse effects*; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects*; D011317:Priapism / Q000139:chemically induced*; D000068581:Tadalafil
chemical_list: D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil